, Volume 32, Issue 6, pp 619–625 | Cite as

In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion

  • Su Jung KimEmail author
  • Joon Won Lee
  • Hye Young Kang
  • So Young Kim
  • Yeon Kyeong Shin
  • Kwang Woo Kim
  • Jun Seok Oh
  • Ki Jung Lim
  • Ji Young Kim
Short Communication



CT-P6 is a biosimilar of trastuzumab, a monoclonal antibody targeting human epidermal growth factor 2 (HER2), that is used in the treatment of breast and gastric cancers.


The aim of this study was to evaluate the in-use physicochemical and biological stability of CT-P6 following preparation for intravenous (IV) infusion.


One batch of CT-P6 within the final month of its 48-month shelf life was used to simulate sub-optimal administration conditions. CT-P6 dilutions of 0.4, 1.0, and 4.0 mg/mL, representative of actual use scenarios, were prepared in 0.9% saline solution in either polypropylene (PP) or polyvinylchloride (PVC) infusion bags. Following refrigeration at 2–8 °C for 1 month, samples were incubated at room temperature for 24 h. Physicochemical and biological stability were evaluated according to presence of sub-visible particles, pH, proportion of molecular weight variants, oxidation level of methionine residues 107, 255/256 and 432/433, and binding affinity to the Fc neonatal receptor and HER2.


Analyses of CT-P6 preparations at all concentrations tested and in both PP and PVC infusion bags revealed no changes in sub-visible particles, pH, molecular weight variants, oxidation, or potency after 1 month at 2–8 °C followed by exposure to room temperature for 24 h.


These analyses demonstrate the extended stability, after refrigerated storage for 1 month followed by 24-h exposure to room temperature, of CT-P6 under the dilution conditions required for IV infusion. This stability was sustained for all dilution factors and both infusion bag materials tested.



Medical writing support (including development of a first and subsequent drafts in consultation with the authors, assembling tables and figures, collating author comments, copyediting, fact checking, and referencing) was provided by Emma Prest, PhD at Aspire Scientific (Bollington, UK) and was funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Drafts were reviewed by Sang-Wook Yoon, PhD and Dasom Choi at Celltrion Healthcare Co., Ltd.

Compliance with Ethical Standards


This study was sponsored by Celltrion, Inc.

Conflict of interest

All authors are employees of Celltrion, Inc. The authors have no other conflicts of interest related to this work.

Author contributions

SJK and JWL were involved in the conception and design of this study. SJK, JWL, HYK, SYK, YKS, KWK, JSO, KJL, and JYK were involved in the acquisition, analysis, and/or interpretation of the data. SJK, JWL, HYK, SYK, YKS, KWK, JSO, KJL, and JYK developed the manuscript and approved the final version for submission.

Supplementary material

40259_2018_314_MOESM1_ESM.pdf (1.1 mb)
Supplementary material 1 (PDF 1105 kb)


  1. 1.
    Esteva FJ, Saeki T, Kim H, Stebbing J. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. Future Oncol. 2018;14(19):1909–19.CrossRefPubMedGoogle Scholar
  2. 2.
    Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist. 2011;16(6):800–10.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    United States Food and Drug Administration. Herceptin prescribing information. Accessed 17 April 2018.
  4. 4.
    European Medicines Agency. Herzuma. Summary of opinion. 2017. Accessed 17 April 2018.
  5. 5.
    European Medicines Agency. Herzuma. Summary of product characteristics. 2018. Accessed 17 April 2018.
  6. 6.
    Sreedhara A, Glover ZK, Piros N, Xiao N, Patel A, Kabakoff B. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci. 2012;101(1):21–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009;98(4):1201–5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    International Conference on Harmonization Guideline. Stability testing of new drug substances and products Q1A(R2). 2003. Accessed 19 April 2018.
  9. 9.
    International Conference on Harmonization Guideline. Stability testing of biotechnological/biological products Q5C. 1995. Accessed 19 April 2018.
  10. 10.
    Pabari RM, Ryan B, Ahmad W, Ramtoola Z. Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions. Curr Pharm Biotechnol. 2013;14(2):220–5.PubMedGoogle Scholar
  11. 11.
    Kaiser J, Kramer I. Physicochemical stability of diluted trastuzumab infusion solutions in polypropylene infusion bags. Int J Pharm Compd. 2011;15(6):515–20.Google Scholar
  12. 12.
    European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: quality issues (revision 1). 2014. Accessed 19 April 2018.
  13. 13.
    Food and Drug Administration. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. 2015. Accessed 19 April 2018.
  14. 14.
    European Medicines Agency. Note for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution. 1998. Accessed 18 April 2018.
  15. 15.
    Herrmann JE, Collins MF. Quantitation of immunoglobulin adsorption to plastics. J Immunol Methods. 1976;10(4):363–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci. 2008;97(8):2924–35.CrossRefPubMedGoogle Scholar
  17. 17.
    Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol. 2009;46(8–9):1878–82.CrossRefPubMedGoogle Scholar
  18. 18.
    Monnet C, Jorieux S, Urbain R, Fournier N, Bouayadi K, De Romeuf C, et al. Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions. Front Immunol. 2015;6:39.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bee JS, Randolph TW, Carpenter JF, Bishop SM, Dimitrova MN. Effects of surfaces and leachables on the stability of biopharmaceuticals. J Pharm Sci. 2011;100(10):4158–70.CrossRefPubMedGoogle Scholar
  20. 20.
    European Pharmacopoeia 6.0. 2.9.19. Particulate contamination: sub-visible particles. 2008. Accessed 17 Apr 2018.

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Su Jung Kim
    • 1
    Email author
  • Joon Won Lee
    • 1
  • Hye Young Kang
    • 1
  • So Young Kim
    • 1
  • Yeon Kyeong Shin
    • 1
  • Kwang Woo Kim
    • 1
  • Jun Seok Oh
    • 1
  • Ki Jung Lim
    • 1
  • Ji Young Kim
    • 1
  1. 1.R&D Division, Biotechnology Research InstituteCelltrion Inc.IncheonKorea

Personalised recommendations